A collagenase digestion method for bioassay of antibiotics in ocular tissues

Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin

AIMS

To evaluate vancomycin penetration into human corneal stromal tissue in patients treated with topical vancomycin eyedrops before penetrating keratoplasty (PKP).

METHODS

Twenty four patients who underwent PKP, seven patients with keratoconus (group 1) and 17 patients with corneal scar or corneal decompensation (group 2). All patients received topical application of vancomycin eyedrops (concentration: 33 mg/ml) 10, 3, 2, 1 hour, and 15 minutes before the operation. Corneal cumulative vancomycin levels were assessed by bioassay.

RESULTS

Mean vancomycin corneal stromal tissue concentration was 46.7 (SE 4.11) microg/g tissue. This value was four to 20-fold in excess of the MIC90 of vancomycin in Staphylococcus aureus (2-10 microg/ml).

CONCLUSIONS

Vancomycin reached high corneal tissue concentrations that significantly exceeded the MIC90 (2-10 microg/ml) for most key Gram positive corneal pathogens. The ratio of vancomycin stromal concentration to protein concentration was statistically higher in group 2 (non-keratoconus).

The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970-2000

The editors of this Festschrift asked us to review the use of antibiotics for the treatment of bacterial conjunctivitis and keratitis over the past 25 years, a period coinciding with the life of the Castroviejo Corneal Society. We believe it is more appropriate to begin our review in the late 1960s. about the time that experimental and clinical studies and algorithms for the clinical care derived from these studies helped shape a more rigorous approach to therapy. Those years saw the introduction of antibiotics that were adapted for ophthalmic use, many of which are still being used today. We will give more weight to our review of keratitis than conjunctivitis.

Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields

We investigated the ability of liposomes to deliver the immunosuppressive agent cyclosporine A (CsA) to the cornea, anterior sclera, aqueous humor, and vitreous in rabbit eyes. One drop (10 microliters) of liposome-encapsulated CsA (CsA-LIP) or olive oil drops containing an equivalent concentration of CsA (CsA-DR) were administered at 15-minute intervals within the first hour and then one hourly over a 6-hour period. In addition, collagen shields soaked for 30 minutes in the liposome preparation (CsA-LIP-CS) were tested in vitro and in vivo as a new drug delivery approach. CsA levels were measured by fluorescence-immunoassay after 1, 3, or 6 hours of drug administration. CsA levels in this study were highest in cornea and anterior sclera. In animals receiving either CsA-DR or CsA-LIP, CsA levels generally increased from 1 to 6 hours. In animals receiving a single application of CsA-CS-LIP, CsA levels peaked at 3 hours and declined at 6 hours in cornea and sclera. CsA-LIP and CsA-CS-LIP delivered significantly higher levels of CsA to the cornea and sclera at 1 and 3 hours than CsA-DR. In aqueous and vitreous humor, CsA levels increased from 1 to 6 hours in animals receiving either CsA-DR or CsA-LIP. On the other hand, animals receiving a single application of CsA-CS-LIP had lower levels of CsA at 6 hours than at the earlier time points. Animals receiving CsA-LIP or CsA-CS-LIP had significantly higher levels of CsA in aqueous and vitreous humor at 1, 3, and 6 hours than animals receiving CsA-DR.(ABSTRACT TRUNCATED AT 250 WORDS)

Pharmacokinetics of aztreonam in rabbit eyes

Subconjunctival injection of 100 mg of aztreonam in rabbits with Pseudomonas aeruginosa endophthalmitis produced transiently high antibiotic concentrations in most intraocular sites. Concentrations of approximately 2.5 micrograms/ml were achieved in the vitreous humor 15 min after injection and persisted for 6 h. Repeated intramuscular injections in dosages of 25 mg/kg every 4 h resulted in drug concentrations in the vitreous humor of 2.4 micrograms/ml in infected eyes. These levels might be adequate for the treatment of intraocular infections caused by highly susceptible organisms. Direct intravitreal injection of 100 micrograms of aztreonam in normal rabbit eyes produced an estimated peak concentration in the vitreous humor of 62 micrograms/ml, with a half-life of 7.5 h, which declined to 6 micrograms/ml by 48 h. The pharmacokinetic indices suggest that, like other beta-lactam antibiotics, aztreonam is eliminated from the vitreous humor by the retinal route. This novel antibiotic warrants further study of its efficacy and toxicity to determine whether it may be a useful alternative to the aminoglycosides for selected cases of ocular infection.

Penetration of ocular tissues and fluids by moxalactam in rabbits with staphylococcal endophthalmitis

Moxalactam was administered subconjunctivally in 100-mg doses to rabbits with infected eyes (Staphylococcus aureus endophthalmitis). High concentrations of drug were detected in the sclera, cornea, and choroid; much lower levels were found in the retina, whereas peak concentrations in the vitreous were about 6 microgram/ml. Repeated intramuscular injections of 50 mg/kg every 4 h produced peak serum levels of about 100 microgram/ml. A gradient between the choroid and the retina was again evident, and peak vitreous levels were about 6 microgram/ml after six injections. These data are consistent with the concept of a blood-retina barrier analogous to the blood-brain barrier. Moxalactam appears to penetrate the eye somewhat better than do other beta-lactams; however, the peak levels produced in the vitreous humor in this animal model were below the level required to inhibit most strains of Pseudomonas aeruginosa.